Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBT: 2023-2024

Historic EBT for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$42.3 million.

  • Contineum Therapeutics' EBT fell 83.67% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 282.33%. This contributed to the annual value of -$42.3 million for FY2024, which is 282.38% down from last year.
  • Per Contineum Therapeutics' latest filing, its EBT stood at -$42.3 million for FY2024, which was down 282.38% from $23.2 million recorded in FY2023.
  • Contineum Therapeutics' EBT's 5-year high stood at $23.2 million during FY2023, with a 5-year trough of -$42.3 million in FY2024.
  • For the 2-year period, Contineum Therapeutics' EBT averaged around -$9.5 million, with its median value being -$9.5 million (2023).
  • Data for Contineum Therapeutics' EBT shows a maximum YoY plummeted of 282.38% (in 2024) over the last 5 years.
  • Contineum Therapeutics' EBT (Yearly) stood at $23.2 million in 2023, then slumped by 282.38% to -$42.3 million in 2024.